Midatech launch treatment to reduce chemo-induced vomiting in the US

pharmafile | April 11, 2016 | News story | Research and Development, Sales and Marketing chemotherapy, midatech, nausea, oncology, radiation, vomiting 

Midatech Pharma (NASDAQ: MTP) has the full commercial launch of Zuplenz (ondansetron) in the US. The drug is an oral soluble film to prevent post-operative, chemotherapy and radiation-induced nausea and vomiting.

Shares of the company rose sharply ahead of the launch of Zuplenz, which Midatech acquired from Galena Biopharma in December. It is approved by the FDA for use in adults and children. The oral soluble films offers an approach to ondansetron delivery that provides several key cancer patient benefits that other solutions don’t, according to the company. Midatech has significantly expanded its commercial operation in terms of personnel ahead of the launch.

Dr Jim Phillips, chief executive officer of Midatech, says: “Zuplenz is a valuable treatment option that offers convenient relief from one of the most debilitating side-effects of common cancer treatments. The product launch of Zuplenz represents yet another step forward for Midatech and further leverages our commercial infrastructure in the US.”

Jerilyn Arnold, oncology nurse specialist at Texas Oncology, comments: “Zuplenz provides an excellent localised therapy solution for the treatment of both chemotherapy-induced nausea and vomiting and radiotherapy-induced nausea and vomiting.”

Sean Murray

Related Content

Genentech shares positive results from phase 3 trial for breast cancer treatment

Genentech, a member of the Roche Group, has announced positive results from the phase 3 …

Evotec and Dewpoint Therapeutics enter strategic partnership

Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …

First patient dosed in Transgene and BioInvent’s phase 1 trial

Transgene and BioInvent have announced that the first patient has been treated in the phase …

Latest content